BACKGROUND. Despite implementation of recommended best practices, our central line-associated bloodstream infection (CLABSI) rates remained high. Our objective was to describe the impact of chlorhexidine gluconate (CHG) bathing on CLABSI rates in neonates.
Neonates in neonatal intensive care units (NICUs) are eshigh despite compliance with standard measures, additional pecially susceptible to healthcare-associated infections interventions can be considered. (HAIs), given their immature immune system, the acuity of Chlorhexidine gluconate (CHG) is a broad-spectrum topcare needed, and the frequency of invasive procedures perical antiseptic that is used in many different clinical settings formed.
1 ' 2 Moreover, HAIs have documented major impacts to prevent infections. 7, 8 Daily bathing with 2% CHG can preon premature infants outcomes. They have been associated vent CLABSI and other HAIs in adult settings 9 " 13 and in pewith a 2-fold increase in the risk of death. 3 Postnatal sepsis diatric intensive care units (ICUs). 14 However, given the pauoccurring in infants born before 30 weeks of gestation has city of safety data in infants less than 2 months of age, CHG been associated with a 2-fold increase in the risk of cerebral use in NICUs has not been fully endorsed in HAI prevention palsy at 2 years of age. 4 Finally, coagulase-negative staphyguidelines. 6 A recent survey in US NICUs revealed that most lococcus bloodstream infections have been associated with a units use CHG and, in most cases, without birth weight or 5.6-fold increase in the risk of cerebral palsy at 18-24 months age restrictions. 15 Given these data and because of high of age (95% confidence interval [CI], 1.9-16.7). 5 CLABSI incidence rates in our NICU, our CLABSI prevention Central line-associated bloodstream infections (CLABSIs) team implemented CHG bathing for a subgroup of infants are an important cause of morbidity and mortality in neowith central venous catheters (CVCs) as part of routine care. nates. 1 Consensus guidelines have recommended measures Because there are currently no data on the use of CHG bathand bundled practices. 6 However, when infection rates remain ing for the prevention of CLABSI in the NICU setting, our objective was to describe the impact of CHG on CLABSI rates in our NICU population.
M E T H O D S

Study Setting and Population
The 
Infection Control Program
During the study period and regardless of birth weight and chronological and gestational age, CHG was used for skin antisepsis prior to CVC insertion and for dressing change. Table 1 summarizes our CHG and bathing protocol in the baseline period (before April 1, 2012). After April 1, 2012, with the support of the NICU leadership and clinical nurse practitioners, infants with a CVC and a birth weight greater than 1,000 g were bathed with a 2% CHG-impregnated cloth (Sage Products), following the same bathing schedule as described in Table 1 . Use of CHG for CVC insertion and dressing change remained unchanged. Infants with a birth weight of 1,000 g or less were bathed with a mild soap until day of life 28, after which time a 2% CHG-impregnated cloth was used. Nurses used 2 CHG wipes per infant per bath. Clinical care protocols were similar for all infants in the NICU. Adverse events reporting was done by NICU nurses and reported to the program manager.
Study Design and Outcome
We used a quasi-experimental design to compare neonates eligible for CHG bathing (infants with a CVC and a birth weight greater than 1,000 g and those with a birth weight of 1,000 g or less after day of life 28) before and after the change in policy. As an additional control group to account for temporal trends, we compared a subgroup of infants with a birth weight of 1,000 g or less aged less than 28 days who were not eligible for CHG bathing and received the same bathing practice during both periods (mild soap). Our primary outcome was the incidence of CLABSI per 1,000 CVC-days in the baseline and intervention periods in infants bathed and not bathed with CHG. 20 Central lines were defined as intravenous catheters that ended at or near the heart or in a great vessel.
HAI
The number of patient-days was defined as the total number of days that patients spent in the NICU. The number of CVC-days was defined as the total number of days of exposure to at least 1 CVC and was collected daily.
21,22
Statistical Analysis
We calculated CLABSI rates per 1,000 CVC-days (CLABSI episodes divided by number of central line-days x 1,000) by year. The device utilization ratio was calculated by dividing the total number of CVC-days by the total number of patientdays. Incidence rate ratios (IRRs) were calculated to compare CLABSIs/1,000 CVC-days during the baseline (2009-2012) and intervention (2012-2013) periods. We first looked at the IRR in the baseline period to determine if there were a significant time trend before pooling all the baseline data together. We used Poisson regression (PROC GENMOD) to adjust for confounding variables: distribution of birth weight categories and year. To control for temporal trends, we compared patients that were eligible for CHG between the baseline and intervention periods and patients that were not eligible for CHG between the same 2 periods. Statistical significance was determined using 2-sided P values (P<.05). All statistical analyses were done using SAS 9.2 (SAS Institute).
RESULTS
During the study period, 1,571 infants were admitted to the NICU, of which 790 had a CVC. Table  3 ). The device utilization ratio varied from 0.43 to 0.58. During the baseline period, there was a non-statistically significant reduction in CLABSI rates, with an adjusted incidence rate ratio (aIRR) of 0.86 (95% CI, 0.63-1.16) when all patients were analyzed together. When looking only at the CHG group and the non-CHG group separately during the baseline period, CLABSI rates did not show a significant time trend (P = .58 and 0.13, respectively). In the non-CHG group-that is, infants with a birth weight of 1,000 g or less, aged less than 28 days-CLABSI rates remained stable, from 8.57 in the reference period to 8.62/ 1,000 CVC-days during the intervention period (cIRR, 1.01 [95% CI, 0.10-5.62]). Once adjusted for the distribution of birth weight categories, the aIRR was 0.86 (95% CI, 0.17-4.44).
Impact on CLABSI Rates
Adverse Events
There was no dermatitis or adverse event reported during the 2012-2013 period.
DISCUSSION
The implementation of CHG bathing for select infants in the NICU with CVCs significantly reduced CLABSI rates and was well tolerated without reported adverse events. The group of infants not CHG bathed did not see any change in their CLABSI rate between the baseline and intervention periods, while the CHG-bathed group saw a decrease of more than 65% in their rates, even when adjusted for the distribution of birth weight categories. These elements support the fact that in our NICU, CHG bathing was effective in decreasing CLABSI rates while other measures put into place to decrease CLABSI rates remained unchanged.
Our results are in keeping with previous reports of CHG bathing effectiveness in other ICU populations. In adult ICUs, CHG bathing was associated with a 50% reduction in CLABSI rates 14 Our study is, to our knowledge, the first study to report the use of CHG bathing to decrease CLABSI rates in the NICU population.
NICU teams have been reticent to use CHG in their patient population because of concerns with adverse events, mainly skin irritation. Some studies have noted potential CHG absorption in very premature infants, given their immature skin, and reflections on hexachlorophene, a topical antiseptic that was used to control staphylococcal colonization in newborn infants. Previous reports had shown an association between the use of 3% hexachlorophene soap, a chlorinated phenol, as a topical antiseptic detergent in premature infants and the development of vacuolar encephalopathy of the brain stem reticular formation. 23, 24 Absorption of hexachlorophene has been documented, with blood levels ranging from 148 to 4,350 ng/L and a significant correlation between blood concentration and infants' weight, skin condition, and gestational age. 25 Chlorhexidine, a chlorinated cationic biguanide, is not related to hexachlorophene and is commonly used in North American NICUs; 61% of 90 NICUs in the United States reported using CHG, most commonly for CVC skin preparation, without age or birth restrictions. 7 A recent survey of Canadian tertiary care pediatric hospitals and US freestanding children's hospitals also showed that 5 of 50 NICUs (10%) used CHG for bathing. 26 CHG has been detected in the blood of some preterm and term infants after whole body washing: in 95% of 10 infants when the sample was a capillary blood and in 5% of 17 infants when the sample was a venous blood taken 12 hours after bathing, with levels ranging from 91 to 460 /*g/L. According to the authors, CHG concentrations found in capillary blood samples were likely due to topical contamination. 27 In another study, CHG-when used for skin antisepsis prior to CVC placement in neonates weighing 1,500 g or more who were 7 days or older-was not associated with dermatitis. Of the 48 enrolled infants, 7 (14.6%) had detectable CHG concentrations ranging from 13 to 100 ptg/L. 28 A study of 20 preterm neonates, with a median gestational age of 28 2/7 weeks, who had 1 limb washed with a 2% CHGimpregnated cloth before peripherally inserted central catheter placement showed that 10 had detectable CHG concentrations with levels ranging from 1.6 to 206 /xg/L; no infant developed a dermatitis. 29 In children aged greater than 3 months, CHG blood level was detected after CHG bathing in 1 of 12 (8.3%) children enrolled, at a concentration of 57 jtfg/L, with no evidence of CHG accumulation. 30 A study of neonatal rhesus monkeys washed daily with CHG did not show any absorption through the skin, even after repeated washing with an 8% CHG solution for 90 days. 31 Despite extensive use and evidence that some absorption occurs, CHG has not been associated thus far with any documented neurological adverse event, except when instilled directly in the middle ear. 27 In the context of a NICU with high CLABSI rates, where bloodstream infections and sepsis in preterm infants have documented adverse outcomes in terms of neurological development and mortality, 4, 5 ' 32 benefits of decreasing the incidence of CLABSI outweigh the theoretical risk that could be associated, although not proven, with CHG use. Finally, repeated use of CHG for bathing has not been associated with increasing minimum inhibitory concentrations or development of resistance in exposed bacterial strains. 33 " 36 Our study has some limitations. First, because CHG bathing was part of a clinical care protocol, we cannot speculate on compliance to guidelines; we therefore analyzed our data using an intent-to-treat analysis. Comparing groups of infants who were CHG bathed and not bathed, regardless of the compliance to CHG bathing, would tend to decrease the magnitude of the association found because of dilution of the exposure in the CHG bathed group. Moreover, we noted a decrease in our device utilization ratio in the fourth year of study. We were not able to say whether this decrease was due to faster removal of unnecessary CVCs or secondary to decreased need for intravenous access for antimicrobials as a consequence of lower CLABSI rates. Our policy always included early removal of unnecessary CVCs, which did not change during the study period. In terms of CHG safety, we monitored only for dermatitis. Finally, because our NICU does not have in-hospital deliveries, our NICU does not tend to admit very small and young premature babies. In fact, an important proportion of our patient population are either admitted for surgical reasons-yet born at 35 weeks or greater-or are premature infants that are older when transferred to our unit. Therefore, our results and findings may not be generalized to all NICUs.
In conclusion, while all other preventive measures for the prevention of CLABSI remained unchanged in our NICU, as supported by the stable CLABSI rates in our control population of non-CHG-bathed infants, the use of 2% CHGimpregnated cloths for bathing was effective in decreasing CLABSI rates. Its use should thus be considered, under specific circumstances, when other preventive measures have failed.
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